Company: ARWR
Filing Date: 2025-11-25
Form Type: 10-K
Source: 0000879407-25-000029
Chunk: 169

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-11-25
Form: 10-K
Item: Item 8
Chunk 169
---
 them and in their name, place and stead, in any and all capacities, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: 

SignatureTitleDate/s/ Christopher AnzaloneChief Executive Officer, President and Director, Chairman of the Board of Directors  (Principal Executive Officer)November 25, 2025Christopher Anzalone/s/ Daniel ApelChief Financial Officer (Principal Financial and Accounting Officer)November 25, 2025Daniel Apel/s/ Mauro FerrariDirectorNovember 25, 2025Mauro Ferrari/s/ Douglass IngramDirectorNovember 25, 2025Douglass Ingram/s/ Hongbo LuDirectorNovember 25, 2025Hongbo Lu/s/ Adeoye OlukotunDirectorNovember 25, 2025Adeoye Olukotun/s/ Michael S. PerryDirectorNovember 25, 2025Michael S. Perry/s/ Victoria VakienerDirectorNovember 25, 2025Victoria Vakiener/s/ William WaddillDirectorNovember 25, 2025William Waddill

80